A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : PV / polycythemia vera

[Related PubMed/MEDLINE]
Total Number of Papers: 1524
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   PV  (>> Co-occurring Abbreviation)
Long Form:   polycythemia vera
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2017 A novel assay to detect calreticulin mutations in myeloproliferative neoplasms. CALR, ET, PMF
2017 Alox5 Blockade Eradicates JAK2V617F-Induced Polycythemia Vera in Mice. ALOX5
2017 Analysis of thrombosis and bleeding complications in patients with polycythemia vera: a Turkish retrospective study. ---
2017 Bone marrow microvessel density and plasma angiogenic factors in myeloproliferative neoplasms: clinicopathological and molecular correlations. BM, ET, MPNs, MVD, PMF
2017 Bone mineral density and microarchitecture in patients with essential thrombocythemia and polycythemia vera. DXA, ET, HR-pQCT
2017 Bumpy road to the diagnosis of polycythaemia vera. ---
2017 Can pegylated interferon improve the outcome of polycythemia vera patients? HU, PEG-IFN
2017 Chronic kidney disease in the BCR-ABL1-negative myeloproliferative neoplasm: a single-center retrospective study. CI, CKD, eGFR, MPNs
2017 Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis. ET, MPN, PMF
10  2017 Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. ET, MPNs, PMF
11  2017 Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey. ET, MF, MPN, MPNs
12  2017 Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera. ET, hs-CRP, MPNs, PTX3
13  2017 Emerging treatments for classical myeloproliferative neoplasms. MPN
14  2017 FAS/FASL gene polymorphisms in Turkish patients with chronic myeloproliferative disorders. CMPD, ET, PMF
15  2017 Interferon induced thrombotic microangiopathy (TMA): Analysis and concise review. CKD, CML, HCL, HCV, HUS, IFN, MS, TMA, TTP
16  2017 Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera. MPNs
17  2017 Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy. BAT, PRO
18  2017 Medical Management of Extensive Arterial Thromboembolism in a Patient with Essential Thrombocythemia and Warfarin Failure. ET, PMF
19  2017 Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib. MF, MPNs, RUX
20  2017 MLF1IP promotes normal erythroid proliferation and is involved in the pathogenesis of polycythemia vera. MLF1IP
21  2017 Monocytosis in Polycythemia Vera: Clinical and Molecular Correlates. CMML, MFFS, WHO
22  2017 Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms. CMPNs, ET, PMF
23  2017 Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway. ET, MF, MPN, RS, SMR
24  2017 Novel hematological parameters for the evaluation of patients with myeloproliferative neoplasms: the immature platelet and reticulocyte fractions. ET, IPF, IRF, MF, MPNs
25  2017 Polycythemia causing posterior segment vascular occlusions. CRAO
26  2017 Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. AVWS, ET
27  2017 Polycythemia Vera Management and Challenges in the Community Health Setting. ---
28  2017 Prognostic impact of bone marrow fibrosis in polycythemia vera: validation of the IWG-MRT study and additional observations. BM, MFFS, MPN
29  2017 Proliferative characteristics of Philadelphia-negative myeloproliferative neoplasms - clinical implications. BM, CFC, EC, ET, PB, Ph- MPN, PMF
30  2017 pSTAT5 and ERK exhibit different expression in myeloproliferative neoplasms. ET, MPNs, PMF
31  2017 Quantitative Proteome Heterogeneity in Myeloproliferative Neoplasm Subtypes and Association with JAK2 Mutation Status. CALR, ET, MPN, PMF
32  2017 Real world epidemiology of myeloproliferative neoplasms: a population based study in Korea 2004-2013. ET, MPNs, PMF
33  2017 Risk factors for vascular complications and treatment patterns at diagnosis of 2389 PV and ET patients: Real-world data from the Swedish MPN Registry. EPO, ET, MPN
34  2017 Sequential analysis of 18 genes in polycythemia vera and essential thrombocythemia reveals an association between mutational status and clinical outcome. ET, MPN
35  2017 Targeted next-generation sequencing identified novel mutations in triple-negative myeloproliferative neoplasms. ET, MPN, TN
36  2017 The Calreticulin control of human stress erythropoiesis is impaired by JAK2V617F in polycythemia vera. CALR, DEX, GR, N-CALR, proEry
37  2017 The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF). TSS-C
38  2017 The potential role of hematocrit control on symptom burden among polycythemia vera patients: Insights from the CYTO-PV and MPN-SAF patient cohorts. ---
39  2017 VEGF-A, sVEGFR-1, and sVEGFR-2 in BCR-ABL negative myeloproliferative neoplasms. ET, MPNs, PMF
40  2017 Whole-exome sequencing identifies novel candidate predisposition genes for familial polycythemia vera. ---
41  2016 A t(11;14)(p13;q11.2) in myelofibrosis following polycythemia vera. MF
42  2016 Acquired uniparental disomy of chromosome 9p in hematologic malignancies. aUPD, MPNs
43  2016 Acute Lymphoblastic Leukemia in the Course of Polycythemia Vera: A Case Report and Review of Literature. ALL
44  2016 Acute Lymphoblastic Leukemia Transformation in Polycythemia Vera: A Rare Phenomenon. ALL, HU
45  2016 After 10years of JAK2V617F: Disease biology and current management strategies in polycythaemia vera. ---
46  2016 Anesthetic management of a patient with polycythemia vera for neurosurgery. ---
47  2016 Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera. ET, MPN, NGS, PMF
48  2016 Application of mutant JAK2V617F for in vitro generation of red blood cells. EPO, HSCs, mJAK2, RBCs, wJAK2
49  2016 Association of TNF polymorphisms with JAK2 (V617F) myeloproliferative neoplasms in Brazilian patients. ET, MPNs, PMF, TNF-alpha
50  2016 Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. ET, MPN, PMF
51  2016 Blood donation and risk of polycythemia vera. CIs, ORs, SIRs
52  2016 Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy. MPN-SAF, PGIC, PSIS, QOL
53  2016 Characteristics and treatment of polycythemia vera patients in clinical practice: a multicenter chart review on 1476 individuals in Germany. ---
54  2016 Characterization and Prognosis Significance of JAK2 (V617F), MPL, and CALR Mutations in Philadelphia-Negative Myeloproliferative Neoplasms ET, Ph-negative MPNs, PMF
55  2016 Characterization of CD34+ hematopoietic progenitor cells in JAK2V617F and CALR-mutated myeloproliferative neoplasms. ET, HPCs, HSCs, MF, MPN
56  2016 Chronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed: clinical and biological characteristics. CLL, ET, MPN, PMF
57  2016 Clinical characteristics of aquagenic pruritus in patients with myeloproliferative neoplasms. AP, MPN
58  2016 Clinical Characteristics of Cerebrovascular Pathology with Patients Suffering from Ph-Negative Myeloproliferative Disease. CVD, ET, MPD, PM
59  2016 Clinical Features of 294 Turkish Patients with Chronic Myeloproliferative Neoplasms. ET, MPNs
60  2016 Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring CALR, JAK2V617F, JAK2Ex12del, and MPLW515L/K mutations. ET, NAP
61  2016 Coexisting JAK2V617F and CALR Exon 9 Mutation in Essential Thrombocythemia. CALR, ET, PMF
62  2016 Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype? ET, PMF
63  2016 Comprehensive Gene expression meta-analysis and integrated bioinformatic approaches reveal shared signatures between thrombosis and myeloproliferative disorders. DEGs, ES, ET, MPDs
64  2016 Construction of polycythemia vera protein interaction network and prediction of related biological functions. OMIM
65  2016 Correlation between JAK2 allele burden and pulmonary arterial hypertension and hematological parameters in Philadelphia negative JAK2 positive myeloproliferative neoplasms. An Egyptian experience. ET, PAH, PMF
66  2016 Detection of CALR Mutation in Clonal and Nonclonal Hematologic Diseases Using Fragment Analysis and Next-Generation Sequencing. CML, ET, MPNs, PMF
67  2016 Detection of JAK2 Exon 12 Mutations in JAK2 V617F-Negative Polycythemia Vera Patients by Cloning Technique. ARMS
68  2016 Determination of prognosis of Philadelphia chromosome-negative myeloproliferative neoplasms with a simple clinical examination: Retrospective analysis of 71 patients in a single institution. EFS, ET, JAK2, MPNs, OS, PMF
69  2016 Diffuse large B-cell lymphoma and polycythemia vera discovered at the onset - a rare association and its possible importance in lymphoma prognosis. DLBCL, MPNs, NHL, R-CHOP
70  2016 Do we need antiplatelet therapy in thrombocytosis? Contra. Proposal for an individualized risk-adapted treatment. ET, MPN, RT
71  2016 Extensive Bone Marrow Necrosis and Osteolytic Lesions in a Case of Acute Myeloid Leukemia Transformed from Polycythemia Vera. AML, BMN
72  2016 Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera. AVWS, ET
73  2016 Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera. CI, HC, HR
74  2016 From leeches to personalized medicine: evolving concepts in the management of polycythemia vera. MPN
75  2016 Genetic Characteristics of Polycythemia Vera and Essential Thrombocythemia in Korean Patients. ET, MPN, SNPs
76  2016 Get a grip on immune cells by inhibiting JAKs. GVHD, MF
77  2016 Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physicians. CH, ET, MPN, OB-P, UH
78  2016 High frequency of JAK2 exon 12 mutations in Korean patients with polycythaemia vera: novel mutations and clinical significance. ---
79  2016 Homozygous calreticulin mutations in patients with myelofibrosis lead to acquired myeloperoxidase deficiency. CALR, EPX, ET, GP, JAK2, MF, MPNs, MPO, mRNA
80  2016 Hormonal and Reproductive Factors and Risk of Myeloproliferative Neoplasms in Postmenopausal Women. CI, ET, HT, MPN
81  2016 How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera. JAK/STAT, MPN, PPV-MF, sAML
82  2016 Idiopathic erythrocytosis: a study of a large cohort with a long follow-up. FE, IE
83  2016 Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET). ET, RT-PCR
84  2016 Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12. CEL, CML, ET, IRRs, IRs, MDS, MPNs, NHWs, RS
85  2016 Incidence, Survival and Prevalence Statistics of Classical Myeloproliferative Neoplasm in Korea. ET, HIRA, KNCIDB, MF, MPN
86  2016 Insights into the Structural Features Essential for JAK2 Inhibition and Selectivity. HCV, JAK2, MPNs, SAR
87  2016 Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms. ET, HDACi, MPN
88  2016 JAK-2 V617F mutation increases heparanase procoagulant activity. CML, ET, PMF, TF, TFPI
89  2016 JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis. ---
90  2016 JAK2 V617F stimulates proliferation of erythropoietin-dependent erythroid progenitors and delays their differentiation by activating Stat1 and other nonerythroid signaling pathways. EPO
91  2016 JAK2V617F Allele Burden Measurement in Peripheral Blood of Iranian Patients with Myeloproliferative Neoplasms and Effect of Hydroxyurea on JAK2V617F Allele Burden. ET, HU, MPNs, PMF, qRT-PCR
92  2016 Laser Photobiomodulation for a Complex Patient with Severe Hydroxyurea-Induced Oral Ulcerations. HU
93  2016 Management of polycythaemia vera: a critical review of current data. ---
94  2016 Masked polycythaemia vera: presenting features, response to treatment and clinical outcomes. BCSH
95  2016 Minihepcidin peptides as disease modifiers in mice affected by beta-thalassemia and polycythemia vera. ---
96  2016 Molecular biomarkers of thrombosis in myeloproliferative neoplasms. CALR, ET, IPSET-Thrombosis, MPN, PMF
97  2016 Molecular testing for JAK2, MPL, and CALR in myeloproliferative neoplasms. ET, PMF
98  2016 Myelofibrosis: an update on drug therapy in 2016. ET, MF, OS, PMF
99  2016 Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey. ET, MF, MPN, MPNs, QOL
100  2016 Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. ET, MF, MPN, MPNs